Our latest Investing Matters Podcast episode with QuotedData's Edward Marten has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Thanks for the summary, it is positive as usual.
What I do not understand is how they did not anticipate the effect that new SOC would have on Sprinter. We are not experts on the metabolic processes in the lungs but SNG should be. We can accept this view:
"Professor Sir Stephen Holgate is clearly a master in his field. His answers were extremely detailed, passionate and he speaks with a certain eloquence and gravitas, which I’m sure is a great asset to Synairgen. "
I wonder what Sir Stephen & his team did not expect about how interferon would function in tandem with SOC or was he unsurprised by results? There was a balls up or silly risk taken or they all had a good idea SOC would meet public health requirements better than SNG (presumably on price) & we carried the can for checking for an unexpected outcome.
That was the best breakfast read in a long time, thank you to Wigster77 and Doc83 for such a detailed account of the mornings events and to Graham for filling in. I think we are all reassured that Team Synairgen are still as passionate and enthusiastic as always, despite that huge February setback, I'm sure it has made them even more determined, they are a strong team.
ThinShins: Just to repeat what I was told by Dr Stacey Adam:
"There is a new inpatient platform protocol called, STRIVE, that is targeted for activation in mid-summer, pending regulatory review"
Few mentions of STRIVE platform trial, can someone please provide a link or explanation what this trial is?
I’ve had google and I can’t pinpoint exactly which trial is being referred to. Thanks and apologies if I missed a explanation or l link that’s already been posted.
Most of you guys are bright enough to pick up on obvious sarcasm, presumably.
Docdaneeka - "They are holding it until a decision on the trial is made."
Yeah they're working overtime to get Covid therapeutics into hospital but they want to delay this particular one for some stupid, illogical reason that seems implausible to anybody who knows what they're actually talking about.
Thanks Doc. I would just be careful not to get your hopes up too much. This journey still has a way to go. As there was no move on a TO before previous trials, I cannot see anything changing this time around. That being said, I do like surprises and a bid would be more than welcomed by everyone. But it is just not likely considering all factors.
Best of luck
RM had to say that.....He like us knows it is likely they are sitting on the results.
But as our CEO he has to preserve a good working relationship and the prospect of a funded
of P3...... !!
I think the inpatient protocol for STRIVE won’t determine when Activ-2 results will materialise. Two separate things.
Docdaneeka - yes, I couldn't quite believe that. But PM was adamant it was still being analysed, but I agree they are holding it until a decision is made. After all, this isn't 1000's of patients.
TO upon announcement of platform trial. Can you explain how and why that would happen, Doc? Across all the boards and forums, nobody else seems to believe this will be the case. Do you have some insight?
Great update Wigster and Doc......thanks for your excellent efforts. Feel much more hopeful / positive of success here now but it's bottom drawer for the time being which is fine.
Roll on Activ-2 and Trial news.
If your drug works the trial can be ended early and as RM said yesterday our drug is number 1 top of the pile for data and efficacy.
Once on a trial anything is possible within that trial window and any company would want to wait until you had results to make a move.
Yesterday was extreme positive
Trialing patients by winter
No need to raise funds
Best data of any drug looking for a PT
Long covid excitement
Peer review soon
Activ2 data positive readout
Strive trial highly likely
Happy Clappy investor today !!
Don't forget that recent platform trials have seen grants for the companies involved in the 10s of millions.
IMHO..... The Board at SNG "believe" that SNG001 will be a commercial drug..
That a Platform trial will go ahead, and most interestingly they want to retain
all of the benefits of that process for shareholders...
Covid is rising significantly during the Summer which is causing huge concerns..
Moreover, hospitalisations are on the rise.... The realisation that the vaccine programme was not
the panacea we hoped for is now acknowledged and the urgent need to address this
is being embraced...
The discussion and responses to Long Covid were a highlight of Doc and Wigs
comprehensive report ..( Thanks again to them both ...) That alone could
make SNG001 a stand out treatment option that appears to have little
if any competition...!!
I think news of a Platform trial is close, and ACTIV 2 results could land
any day.... Many writing this off have sold and hoping nothing
happens short term......
GLA!
For a few weeks now this has felt much like it did in early 2020, the AGM reports on here (thanks guys) have confirmed it.
Commercialisation didn't drive the share price forward then, it was the p2 results. The same will happen again.
When the platform trial is announced it will feel even more like 2020.
What's left of my pre-p2 holding is indeed in the bottom drawer. I'm now going to build a new position and look towards trial results to realise a profit.
When that happens I'll sell some and leave the rest.
I'm getting a sense of deja vu, lol!
This whole saga would make a good MBA Case Study.
How over-confidence can kill a company.
What has stood out for me (as the rest about further trials etc, is well known), was that there is little to no chance of commercialising the product within next 12 mths, and this says it all.
By then Poly would have past the February 21st collapse in Share price so any potential TO will be peanuts. Share price will bounce about and have some good days on announcements of new Trials, but we basically back to Square one! Very long road ahead and a lot of patience needed as will be no significant returns on current value until trials are past and reviewed.
Thanks to the guys reporting, really appreciated, but for me it very depressing reading and info based on the timescales involved. Just shows what a complete disaster Sprinter was for this to move forward.
We have a drug that saves lives but still not enough data to prove it beyond doubt and 20 years of trying going to turn into possibly 22 years before it hits market at best. Not impressed at all.
Its also a wonderful thing that the AAB and inborn error science preprints back in 2020 were first discovered and discussed on this very message board. We then shared the info with the company so us internet sleuths and amateur scientists may have helped in a little way :)
The autoantibodies science in my opinion is a big reason why we may get a 2nd chance with a platform trial. So for me was a key question to be answered at the AGM, the response from the likes of SSH or RM would be very telling.
Wigster/doc
Many thanks for your excellent posting; it is much appreciated.
First class!
Lots of NOs from the Bod in the discussion, which is unsurprising.
‘the main point was that to attract/retain the calibre of people that Synairgen need to push forward and commercialise SNG001, they need salaries to be commensurate with industry standards/levels.’
Interesting and out of touch!
Many thanks, again.
My strategy is the same as Ghias.
Return at monthly/quarterly intervals to see what/if any progress has been made in this long journey.
ATB
Thanks Peelweight and HSD for the Casanova information - explains why the "yes we do know about this!" answer was given in a smiling and enthusiastic way by multiple members of the board.
And once again, thank you all for your appreciation. You're all very welcome and the fact the board has been buzzing with positive debate and renewed (but rightly cautious) enthusiasm makes it all worthwhile.
I like the answer regarding the new commercials hires. Will will be keeping them as there is plenty of work to be done to get us to commercializedsion it will not be a wast of money
I really appreciate the efforts of fellow investors keeping us informed on this Board about our shareholding in Synairgen. In the past I've attended similar AGM's and reported back but can't get to these early meetings any more . So, am all the more grateful to Doc83 and Wigster for their time and efforts. Thank you.